FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’
PYZCHIVA becomes Samsung Bioepis’ seventh biosimilar and fourth immunology biosimilar approved by the FDAPYZCHIVA’s licensing period will begin on February ...
Read morePYZCHIVA becomes Samsung Bioepis’ seventh biosimilar and fourth immunology biosimilar approved by the FDAPYZCHIVA’s licensing period will begin on February ...
Read moreAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.